UnitedHealth Stock Target Raised to $462 by Leerink
Leerink Partners raised its price target on UnitedHealth (UNH) to $462 from $400, keeping a Buy rating. The revision reflects higher operating margin forecasts for Optum Health, now seen at 3.8% in 2027 and 6.5% in 2028.
Key Numbers
Leerink Partners analysts raised their price target on UnitedHealth Group (UNH) to $462 from $400, maintaining a Buy rating. The adjustment reflects improved margin expectations for the company's Optum Health unit, which provides medical care to millions.
Rating Change
- New Price Target: $462
- Previous Price Target: $400
- Rating: Buy (unchanged)
Analyst Rationale
Analysts now forecast Optum Health operating margins of 3.8% in 2027 (up one percentage point from prior) and 6.5% in 2028 (up from 3.4%). The improvement is attributed to operational efficiencies and patient volume growth.
Context
The upgrade follows UnitedHealth's ongoing turnaround efforts, which have shown early signs of success. No other analysts have issued similar updates recently, but the stock has gained investor support.
What to Make of It
The target increase signals analyst confidence in the recovery trajectory, but it is not a buy or sell recommendation. Investors should monitor upcoming earnings to gauge actual performance.
Frequently Asked Questions
Found this useful? Share it